EP1757606B1
(de)
*
|
2001-02-24 |
2009-05-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Xanthinderivate Verwendung als Arzneimittel sowie deren Verfahren zur deren Herstellung
|
US7407955B2
(en)
*
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7687625B2
(en)
*
|
2003-03-25 |
2010-03-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
ZA200508439B
(en)
|
2003-05-05 |
2007-03-28 |
Probiodrug Ag |
Medical use of inhibitors of glutaminyl and glutamate cyclases
|
WO2004103993A1
(en)
|
2003-05-14 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2005000848A1
(en)
*
|
2003-06-20 |
2005-01-06 |
F. Hoffmann-La Roche Ag |
Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
|
CN101090901B
(zh)
*
|
2003-06-20 |
2010-12-15 |
霍夫曼-拉罗奇有限公司 |
作为dpp-iv抑制剂的六氢吡啶并异喹啉类
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN1867560A
(zh)
*
|
2003-08-13 |
2006-11-22 |
武田药品工株式会社 |
4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
|
EP1697342A2
(de)
*
|
2003-09-08 |
2006-09-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitoren
|
EP1699777B1
(de)
*
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidase-hemmer
|
EP1680120A2
(de)
|
2003-11-03 |
2006-07-19 |
Probiodrug AG |
Zusammenstellungen zur behandlung von neuronalen erkrankungen
|
CN1918131B
(zh)
|
2004-02-05 |
2011-05-04 |
前体生物药物股份公司 |
谷氨酰胺酰基环化酶抑制剂
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
MXPA06010571A
(es)
*
|
2004-03-15 |
2007-02-16 |
Takeda Pharmaceutical |
Inhibidores de dipeptidil peptidasa.
|
WO2005097127A2
(en)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Method of treating men with metabolic and anthropometric disorders
|
WO2005118555A1
(en)
*
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
NZ554943A
(en)
*
|
2004-11-30 |
2010-12-24 |
Hoffmann La Roche |
Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
|
WO2006066747A1
(en)
*
|
2004-12-20 |
2006-06-29 |
F. Hoffmann-La Roche Ag |
4-aminopiperidine derivatives
|
EP1828192B1
(de)
*
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidasehemmer
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
CN101175494B
(zh)
*
|
2005-04-26 |
2011-07-13 |
田边三菱制药株式会社 |
用于糖/脂质代谢异常的预防/治疗剂
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
JP2009504599A
(ja)
*
|
2005-08-11 |
2009-02-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
Dpp−iv阻害剤を含有する医薬組成物
|
BRPI0616077B8
(pt)
*
|
2005-09-14 |
2021-05-25 |
Takeda Pharmaceuticals Co |
composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
|
JP5027137B2
(ja)
|
2005-09-14 |
2012-09-19 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤の投与
|
KR101368988B1
(ko)
*
|
2005-09-16 |
2014-02-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
디펩티딜 펩티다제 억제제
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1999108A1
(de)
*
|
2006-03-28 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Herstellung von (r)-3-aminopiperidin-dihydrochlorid
|
EA016041B1
(ru)
|
2006-04-11 |
2012-01-30 |
Арена Фармасьютикалз, Инк. |
Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EA200802054A1
(ru)
|
2006-04-12 |
2009-04-28 |
Пробиодруг Аг |
Ингибиторы фермента
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
CN101437823B
(zh)
|
2006-05-04 |
2014-12-10 |
勃林格殷格翰国际有限公司 |
多晶型
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP2019679B1
(de)
|
2006-05-23 |
2018-06-20 |
Theracos, Inc. |
Glucosetransporthemmer und anwendungsverfahren
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2066667B1
(de)
*
|
2006-09-15 |
2011-08-31 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von pyrido[2,1-a]isochinolinderivaten, das die racematspaltung eines enamins umfasst
|
JP5236649B2
(ja)
*
|
2006-09-15 |
2013-07-17 |
エフ.ホフマン−ラ ロシュ アーゲー |
エナミンの触媒的不斉水素化によるピリド[2,1−a]イソキノリン誘導体の調製方法
|
JP5379692B2
(ja)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP5523107B2
(ja)
|
2006-11-30 |
2014-06-18 |
プロビオドルグ エージー |
グルタミニルシクラーゼの新規阻害剤
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
KR101610005B1
(ko)
*
|
2007-08-17 |
2016-04-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
|
CA2697349C
(en)
|
2007-08-23 |
2012-04-24 |
Theracos, Inc. |
Benzylbenzene derivatives and methods of use
|
US20090163718A1
(en)
*
|
2007-12-19 |
2009-06-25 |
Stefan Abrecht |
PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
EP2146210A1
(de)
*
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
EP2312944B1
(de)
|
2008-07-15 |
2018-09-05 |
Theracos, Inc. |
Deuterierte benzylbenzolderivate und verwendungsverfahren
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
CN103816158A
(zh)
*
|
2008-08-15 |
2014-05-28 |
勃林格殷格翰国际有限公司 |
用于治疗fab-相关疾病的嘌呤衍生物
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
AU2009307884B2
(en)
|
2008-10-22 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CN102271509A
(zh)
|
2008-10-31 |
2011-12-07 |
默沙东公司 |
用于抗糖尿病药的新型环苯并咪唑衍生物
|
CA2745037C
(en)
|
2008-12-23 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
US8486940B2
(en)
|
2009-09-11 |
2013-07-16 |
Probiodrug Ag |
Inhibitors
|
US9457029B2
(en)
|
2009-11-27 |
2016-10-04 |
Boehringer Ingelheim International Gmbh |
Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
KR101790806B1
(ko)
|
2010-03-10 |
2017-11-20 |
프로비오드룩 아게 |
글루타미닐 사이클라제(qc, ec 2.3.2.5)의 헤테로사이클릭 억제제
|
JP2013523819A
(ja)
|
2010-04-06 |
2013-06-17 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
BR112012028136A2
(pt)
|
2010-05-05 |
2016-08-09 |
Boehringer Ingelheim Int |
terapia de combinaçao
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
WO2012018950A1
(en)
|
2010-08-03 |
2012-02-09 |
Beth Israel Deaconess Medical Center |
Methods and compositions for treatment of metabolic disorders
|
WO2012040279A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
BR112013021236B1
(pt)
|
2011-02-25 |
2021-05-25 |
Merck Sharp & Dohme Corp |
composto derivado de benzimidazol, e, composição
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2731947B1
(de)
|
2011-07-15 |
2019-01-16 |
Boehringer Ingelheim International GmbH |
Substituiertes dimeres chinazolin derivat, dessen herstellung und verwendung in pharmazeutischen zusammensetzungen zur behandlung von typ i und typ ii diabetes
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2849755A1
(de)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3110449B1
(de)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medizinische verwendung eines dpp-4-inhibitors
|
WO2016144862A1
(en)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
CN107820496B
(zh)
*
|
2015-07-27 |
2020-11-03 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四环4-氧代-吡啶-3-甲酸衍生物
|
CN105412096A
(zh)
*
|
2015-12-15 |
2016-03-23 |
上海壹志医药科技有限公司 |
药根碱的药物用途
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
EP3606527A1
(de)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Ppar-gamma-agonist zur behandlung der progressiven supranuklearen blickparese
|
DK3461819T3
(da)
|
2017-09-29 |
2020-08-10 |
Probiodrug Ag |
Inhibitorer af glutaminylcyklase
|